NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period†). Baxter develops, manufactures, and markets medical products. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen. ...

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to systemic defects in its Novum IQ Large Volume Pump, which posed serious risks to patients [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter made false or misleading statements regarding the Novum IQ Large Volume Pump, which suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - The company announced on July 31, 2025, a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Points - Baxter International Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to a federal securities class action [1] - Investors are reminded of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action against Baxter [1] Company Overview - Baxter International Inc. is listed on the NYSE under the ticker symbol BAX [1] - Faruqi & Faruqi, LLP is a national securities law firm with offices in New York, Pennsylvania, California, and Georgia [1]

Core Viewpoint - A securities class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered from systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of all individuals or entities that purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter failed to disclose significant issues with the Novum LVP, including systemic defects that caused malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [2]. Group 2: Implications for Baxter - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might have to halt all new sales of these pumps [2]. - The statements made by Baxter regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 3: Investor Actions - Investors who acquired shares of Baxter are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 15, 2025 [3].

LOS ANGELES--(BUSINESS WIRE)---- $BAX--BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

Core Viewpoint - Labaton Keller Sucharow LLP has filed a securities class action lawsuit against Baxter International, Inc. and certain executives, alleging misleading statements regarding the safety and efficacy of the Novum IQ Large Volume Pump, which has been linked to serious patient risks [1][2][4]. Company Overview - Baxter International, Inc. is a global healthcare company that develops and sells medical products for hospitals and healthcare facilities. The company recently launched the Novum IQ Large Volume Pump, which is intended for intravenous fluid delivery [2]. Allegations in the Lawsuit - The lawsuit claims that Baxter and its executives misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, posing serious risks to patients [2]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not adequately address these issues [2]. - The lawsuit also states that Baxter's communications regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Timeline of Events - Safety concerns regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion issues. Baxter issued warning letters to customers about potential risks shortly thereafter [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in the company's stock price [4]. Class Action Details - Individuals who purchased Baxter common stock during the specified class period may seek appointment as Lead Plaintiff in the lawsuit, with a deadline for filing motions set for December 15, 2025 [5].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7][8] Investment Opportunity - Wall Street is investing heavily in AI, but there is a looming energy crisis as AI technologies require vast amounts of electricity, comparable to the consumption of small cities [2][3] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI data centers, making it a potentially lucrative investment [3][8] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses significant nuclear energy infrastructure assets, which are crucial for America's future power strategy, and is capable of executing large-scale engineering projects across various energy sectors [7][8] Financial Health - The company is noted for being debt-free and having a substantial cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] - It also holds a significant equity stake in another AI-related company, providing indirect exposure to multiple growth opportunities in the AI sector [9][10] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off the radar, trading at less than seven times earnings excluding cash and investments [9][10] - The company is recognized for delivering real cash flows and owning critical infrastructure, making it a compelling investment choice in the context of the AI and energy sectors [11][12]

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of Baxter International Inc. (NYSE: BAX ) have been seeing fresh flows as the business continues to struggle. In April, I believed that the situation was messy, yet appealing, if only manag ...

Group 1 - Baxter International Inc. is perceived as a significant disappointment in the market, with a notable recommendation to consider alternatives like Abbott Labs [1] - The company provides a range of medical devices, pharmaceuticals, and digital health technologies, including IV solutions and surgical products [2] - Concerns have been raised regarding Baxter's capital allocation decisions, management changes, and sensitivity to hospital budgets, leading to a shift in investment focus towards Linde [2] Group 2 - Despite its defensive characteristics, Baxter is viewed as less favorable compared to certain AI stocks that present greater upside potential and lower downside risk [2]

Company Overview - Baxter International Inc. (BAX) is headquartered in Deerfield, Illinois, and has a market cap of $11.9 billion, focusing on healthcare products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other medical conditions [1][2] - The company's products are utilized in various healthcare settings, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and research laboratories [1] Market Position - BAX is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical instruments and supplies industry [2] - The company excels through a diversified portfolio of healthcare products and innovative expansions, with strategic acquisitions enhancing its connected care solutions [2] Stock Performance - BAX shares have decreased by 41.5% from their 52-week high of $40.49, reached on September 17, 2024, and have declined 20.5% over the past three months, underperforming the Dow Jones Industrials Average, which gained 9.4% in the same period [3] - Year-to-date, BAX shares are down 18.8%, and over the past 52 weeks, they have fallen 39.8%, significantly lagging behind the Dow Jones Industrials Average's YTD gains of 8.5% and 11.2% returns [4] Financial Performance - In Q2, BAX reported an adjusted EPS increase of 28.3% year-over-year to $0.59, with revenue of $2.8 billion, reflecting a 4.3% increase from the previous year [5] - The company's weak stock performance is attributed to ongoing operational challenges and cautious hospital expenditure, leading to a significant drop in share price following the Q2 results [5]